-+ 0.00%
-+ 0.00%
-+ 0.00%

Genprex preclinical data link low TROP2 levels to Reqorsa resistance in lung cancer

PUBT·11/19/2026 12:04:21
Listen to the news
Genprex preclinical data link low TROP2 levels to Reqorsa resistance in lung cancer
  • Genprex presented preclinical findings identifying TROP2 as a potential predictor of response to Reqorsa gene therapy in non-small cell lung cancer.
  • Results were presented at the EORTC-NCI-AACR Symposium, held November 18-20, 2026, in Barcelona, Spain.
  • Low TROP2 expression was associated with treatment resistance; pretreatment tumor biopsies from clinical trial patients supported the findings.
  • Modifying TROP2 levels increased treatment sensitivity in laboratory models, suggesting a potential strategy to improve Reqorsa’s efficacy.
  • Additional research and prospective clinical evaluation are needed to establish whether TROP2 can guide patient selection.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genprex Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202611190700PR_NEWS_USPR_____DA01577) on November 19, 2026, and is solely responsible for the information contained therein.